News
(NASDAQ: REGN) and Sanofi today presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing Dupixent ® (dupilumab) in adults and adolescents with moderate-to-severe atopic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback